Fertility in male patients with Hodgkin's disease after therapy –results from the German Hodgkin Lymphoma Study Group (GHSG)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 6547-6547
Author(s):  
M. Sieniawski ◽  
A. Josting ◽  
K. Breuer ◽  
T. Sven ◽  
V. Diehl ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Study Group ◽  
Male Patients ◽  
Lymphoma Study Group

Fertility in male patients with Hodgkin's disease after therapy –results from the German Hodgkin Lymphoma Study Group (GHSG)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 6547-6547
Author(s):  
M. Sieniawski ◽  
A. Josting ◽  
K. Breuer ◽  
T. Sven ◽  
V. Diehl ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Study Group ◽  
Male Patients ◽  
Lymphoma Study Group

scholarly journals Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group

2004 ◽  
Vol 15 (7) ◽  
pp. 1079-1085 ◽  
Author(s):  
K. Behringer ◽  
A. Josting ◽  
P. Schiller ◽  
H.T. Eich ◽  
H. Bredenfeld ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Solid Tumors ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Study Group ◽  
Lymphoma Study Group

Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group.

1995 ◽  
Vol 13 (2) ◽  
pp. 403-409 ◽  
Author(s):  
R Munker ◽  
D Hasenclever ◽  
O Brosteanu ◽  
E Hiller ◽  
V Diehl
Keyword(s):  
Bone Marrow ◽  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Bone Marrow Involvement ◽  
Stage Iv ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Prognostic Relevance ◽  
Lymphoma Study Group

PURPOSE To describe the incidence of primary bone marrow involvement (BMI) in Hodgkin's disease (HD) and its correlation with clinical and laboratory features present at diagnosis, and to evaluate the prognostic relevance of BMI. PATIENTS AND METHODS Between 1983 and 1991, 2,307 patients with HD were treated according to two trial generations (HD1-3 and HD4-6) of the German Hodgkin's Lymphoma Study Group (GHSG). RESULTS One hundred thirty-five cases of primary BMI were observed. The incidence of BMI was 4.8% in the HD4-6 study generation, which included all stages. Among stage IV patients, 32% had BMI. Among those with BMI, other organs were also involved in 33%. Among all patients, the presence of BMI was significantly associated with B symptoms, lymph nodes on both sides of the diaphragm, mixed cellularity histologic subtype, leukocytopenia, anemia, thrombocytopenia, lactate dehydrogenase (LDH) level more than 400 U/L, and erythrocyte sedimentation rate (ESR) more than 40 mm/h. BMI was negatively correlated with a large mediastinal tumor (3.7% v 20.0% in non-BMI cases). Eighty-seven of 108 (81%) assessable patients with BMI achieved a complete remission (CR). This compares favorably with the overall CR rate in all stage IIIB/IV patients. Among stage IV patients, BMI has no prognostic relevance with regard to freedom from treatment failure and overall survival. Twenty-one patients with BMI relapsed after having achieved a CR. Only five of these (24%) again had a positive bone marrow biopsy. CONCLUSION The prognosis of patients with BMI is not worse than the prognosis of other advanced-stage HD patients. BMI alone does not define a special high-risk group in which a different treatment approach is indicated.

Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis

2001 ◽  
Vol 19 (7) ◽  
pp. 2026-2032 ◽  
Author(s):  
Ulrich Rueffer ◽  
Andreas Josting ◽  
Jeremy Franklin ◽  
Michael May ◽  
Markus Sieber ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Disease Free Survival ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Lymphoma Study Group ◽  
First Diagnosis

PURPOSE: The cumulative incidence for non-Hodgkin lymphoma’s (NHL) after primary Hodgkin’s disease (HD) ranges between 1% and 6%. To investigate the course of disease for secondary NHL, we retrospectively analyzed patients treated within clinical trials of the German Hodgkin’s Lymphoma Study Group (GHSG) since 1981. PATIENTS AND METHODS: From 1981 to 1998, the GHSG conducted three generations of clinical trials for the treatment of primary HD involving a total of 5,406 patients. Reference histology by an expert panel was obtained for 4,104 of the patients. Data on incidence, treatment, and outcome of secondary NHL were updated in March 1999. RESULTS: At first diagnosis of HD, the pathologists rejected 114 (2.1%) of 5,520 cases initially diagnosed as HD and rediagnosed them as primary NHL. Fifty-two (0.9%) of the remaining 5,406 patients developed a secondary NHL. One patient was excluded from further analyses because of insufficient documentation. Six patients had no further therapy because of patient refusal (n = 1) or rapidly progressive disease (n = 5). For the remaining 45 patients, overall response rate was 43% (36% complete response and 7% partial response). The actuarial 2-year freedom from treatment failure (FFTF) and overall survival (OS) for all patients was 24% and 30%, respectively, and for patients with diffuse large-cell lymphoma, it was 28% and 35%, respectively. Time of occurrence of secondary NHL after first diagnosis of HD and variables employed in the age-adjusted International Prognostic Factor Index (IPFI) significantly influenced treatment outcome. CONCLUSION: In the GHSG, the incidence of secondary NHL with 0.9% is relatively low compared with previously reported series. The prognosis of secondary NHL seems dismal and is significantly influenced by time of occurrence and the age-adjusted IPFI. In a subset of patients with secondary NHL, long-term disease-free survival could be achieved.

Our experiences with treating patients of Hodgkin’s disease in the last decade

2007 ◽  
Vol 148 (15) ◽  
pp. 675-682 ◽  
Author(s):  
Zsófia Simon ◽  
Katalin Keresztes ◽  
Zsófia Miltényi ◽  
Zsuzsanna Ress ◽  
László Váróczy ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease

Bevezetés: A Hodgkin-lymphoma diagnosztikájában, kezelésében az elmúlt évtizedben jelentős változások következtek be. Cél: Ennek tükrében a szerzők célul tűzték ki az 1995–2004 között a DEOEC III. sz. Belgyógyászati Klinikán elsődlegesen kezelt Hodgkin-lymphomás betegek adatainak áttekintését 2006 januárjában, átlagosan 69 (12–132) hónap követés után. Módszerek: a kórtörténetek adatait SPSS statisztikai programmal értékelték. Eredmények: A 163 beteg átlagéletkora a diagnóziskor 36 (14–75) év volt, bimodális koreloszlással. A leggyakoribb (48,5%) a kevert sejtes altípus volt. A betegek 41,1%-a volt korai stádiumú, legkedvezőtlenebb prognózissal 15,7%-uk bírt, bulky tumort 28,2%-ban észleltek. 7 betegnél radioterápiát, 63-nál kemoterápiát és 92-nél tervezett kombinált kezelést alkalmaztak. A sugárkezelések 61,6%-a érintett mezős volt, 61 beteg cyclophosphamid, vincristin, procarbazin, prednisolon, adriamycin, bleomycin, vinblastin; 87 beteg adriamycin, bleomycin, vinblastin, 7 pedig egyéb kemoterápiát kapott. Az elsődleges kezelésre 146 komplett, 10 parciális remisszió jött létre, 6 beteg nem reagált. 10 részleges remisszióban lévő és 5 nem reagáló beteget tovább kezeltek. 27 komplett remisszióban lévő betegnél alakult ki relapszus, közülük 15-nél történt nagy dózisú kezelés autológ perifériás haemopoeticus őssejt-transzplantációval. A követési idő alatt 18 beteg halt meg, 11 a lymphoma progressziója vagy a kezelés szövődménye, 6 második tumor, 1 egyéb ok miatt. Betegeik 10 éves prognosztizált teljes túlélése 83% (részletesen: korai, majd előrehaladott kedvező vs kedvezőtlen: 100% vs 87,8%, 88,9% vs. 41,6%), az eseménymentes 70% (82,6% vs 70,8%, 64,5% vs 0%) volt. Konklúzió: Hodgkin-lymphomás betegeik kezelési eredményei javultak, azonban arra is rámutatnak, hogy a korai, kedvező prognózisú betegeknél a kezelési toxicitás csökkentendő, míg az előrehaladott, rossz prognózisú betegek (az összes beteg kb. 10%-a) agresszívebb primer kezelését akár a súlyosabb mellékhatások, szövődmények ismeretében is vállalni kell.

Sign in / Sign up

Export Citation Format

Share Document